| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.35 | 2e-09 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.35 | 9e-09 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.25 | 6e-05 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.27 | 0.0002 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.22 | 0.002 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.19 | 0.004 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.19 | 0.005 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.17 | 0.01 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.16 | 0.02 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.14 | 0.05 |